UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.13 Billion Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,234,672 shares of the biopharmaceutical company's stock after purchasing an additional 1,605,730 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.98% of Gilead Sciences worth $1,130,117,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. HHM Wealth Advisors LLC increased its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences in the fourth quarter valued at about $28,000. Crews Bank & Trust bought a new position in Gilead Sciences during the 4th quarter worth about $31,000. Stephens Consulting LLC lifted its holdings in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of a number of recent research reports. Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Bank of America increased their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Finally, DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Price Performance

GILD stock opened at $106.16 on Tuesday. The company has a market capitalization of $132.06 billion, a P/E ratio of 286.92, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The business has a 50-day simple moving average of $105.60 and a two-hundred day simple moving average of $99.95. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the firm earned ($1.32) EPS. The company's quarterly revenue was down .3% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 22,929 shares of company stock valued at $2,634,220 over the last ninety days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.